Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?

被引：0
|
作者：
Greenberg, Arthur [1 ]
机构：
[1] Duke Univ, Dept Med, Div Nephrol, Med Ctr, Durham, NC 27710 USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2007年 / 50卷 / 06期
关键词：
D O I：
10.1053/j.ajkd.2007.10.006
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：904 / 907
页数：4
相关论文
共 50 条
  • [41] Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats
    Nishikimi, T
    Kawano, Y
    Saito, Y
    Matsuoka, H
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 27 (02) : 275 - 282
  • [42] Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia
    Ghali, Jalal K.
    Zmily, Hammam D.
    Farah, Jareer O.
    Daifallah, Suleiman
    IDRUGS, 2010, 13 (11) : 782 - 792
  • [43] The V2 receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells
    G. Marroncini
    C. Anceschi
    L. Naldi
    B. Fibbi
    F. Baldanzi
    M. Maggi
    A. Peri
    Journal of Endocrinological Investigation, 2022, 45 : 1693 - 1708
  • [44] The V2 receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells
    Marroncini, G.
    Anceschi, C.
    Naldi, L.
    Fibbi, B.
    Baldanzi, F.
    Maggi, M.
    Peri, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (09) : 1693 - 1708
  • [45] Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure
    Veeraveedu, Punniyakoti T.
    Watanabe, Kenichi
    Ma, Meilei
    Palaniyandi, Suresh S.
    Yamaguchi, Ken'ichi
    Kodama, Makoto
    Aizawa, Yoshifusa
    BIOCHEMICAL PHARMACOLOGY, 2008, 75 (06) : 1322 - 1330
  • [46] Prognostic effect of a vasopressin V2 receptor antagonist in acute congestive heart failure patients with hypoperfusion, the wet-cold pattern
    Matsushita, Kenichi
    Harada, Kazumasa
    Miyamoto, Takamichi
    Iida, Kiyoshi
    Yamamoto, Yoshiya
    Shiraishi, Yasuyuki
    Nagatomo, Yuji
    Yoshino, Hideaki
    Yamamoto, Takeshi
    Nagao, Ken
    Takayama, Morimasa
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (11) : 1795 - 1805
  • [47] Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats
    Takeuchi, M
    Lee, JD
    Shimizu, H
    Ueda, T
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 108 (02) : 231 - 236
  • [48] Vasopressin V2 receptor, tolvaptan, and ERK1/2 phosphorylation in the renal collecting duct
    Khan, Shaza
    Raghuram, Viswanathan
    Chen, Lihe
    Chou, Chung-Lin
    Yang, Chin-Rang
    Khundmiri, Syed J.
    Knepper, Mark A.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2024, 326 (01) : F57 - F68
  • [49] Chronic Administration of Oral Vasopressin Type 2 Receptor Antagonist Tolvaptan Exerts Both Myocardial and Renal Protective Effects in Rats With Hypertensive Heart Failure
    Morooka, Hanako
    Iwanaga, Yoshitaka
    Tamaki, Yodo
    Takase, Toru
    Akahoshi, Yasumitsu
    Nakano, Yoshimasa
    Fujiki, Hiroyuki
    Miyazaki, Shunichi
    CIRCULATION-HEART FAILURE, 2012, 5 (04) : 484 - 492
  • [50] V2 vasopressin receptor mutations
    Makita, Noriko
    Manaka, Katsunori
    Sato, Junichiro
    Iiri, Taroh
    VASOPRESSIN, 2020, 113 : 79 - 99
12345